Presented by:
Michael Rutenberg, MD, PhD
Assistant Professor, Department of Radiation Oncology
University of Florida
UF Health Proton Therapy Institute
Faculty Disclosure:
Dr. Rutenberg has disclosed that he has no relevant financial relationships. No one else in a position to control content has any relationships to disclose.
Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/.
Release Date: May 25, 2021
Expiration Date: May 24, 2022
Target Audience: This course is intended for an audience of specialty physicians, primary care physicians, physician assistants, nurses, as well as others who treat patients with central nervous system tumors.
Learning Objectives:
As a result of participation in this activity, participants should be able to:
- Define proton therapy and describe how proton therapy is different from conventional radiation therapy.
- Identify and determine how the physical properties of protons may improve outcomes in patients with central nervous system tumors.
- Discuss recent clinical study outcomes in neurooncology.
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource(s) for further study:
- Holtzman, A.L., Rotondo, R.L., Rutenberg, M.S. et al. Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. J Neurooncol 142, 557–563 (2019). https://doi.org/10.1007/s11060-019-03129-8
- Dennis ER, Bussiere MR, Niemierko A, et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. Technol Cancer Res Treat. 2013;12(1):1-9. doi:10.7785/tcrt.2012.500276
- Jalali R, Gupta T, Goda J, Goswami S, et al. Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low Grade Brain Tumors: A Randomized Clinical Trial. JAMA Oncol. 2017;1;3(10):1368-1376
- Rutenberg MS, Rotondo RL, Rao D, et al. Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study. J Neurooncol. 2020;147(2):387-395. doi:10.1007/s11060-020-03432-9
For additional information, please contact Christina Mershell at clmershell@floridaproton.org or call (904) 831-4034.